SOLICITATION NOTICE
66 -- QX200 Digital PCR Reader
- Notice Date
- 8/27/2014
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-(HG)-2014-241-DLM
- Archive Date
- 9/19/2014
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Human Genome Research Institute, (NHGRI), intends to negotiate and award a purchase order on a noncompetitive sole source basis Bio-Rad Laboratories, 2000 Alfred Nobel Drive, Hercules, California 94547-1804. (BRAND-NAME: BIO-RAD LABORATORIES: QX200 Digital PCR Reader SYSTEM) Procurement : 1. QX200 Digital PCR Reader, Part Number: 1864003, Quantity: One; 2. QX200 Droplet Generator, Part Number: 1864002, Quantity: One; 3. Automated Droplet Generator, Part Number: 1864101, Quantity: One; 4. Laptop Computer, ddPCR System, Part Number: 1863007, Quantity: One; 5. PX1 PCR Plate Sealer, Part Number: 1814000, Quantity: One; and 6. C1000 Touch Cycler w/96W DP RM., Part Number: 1851197, Quantity: One. BACKGROUND : The National Institute of Health (NIH) mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Human Genome Research Institute (NHGRI) mission has expanded to encompass a broad range of studies aimed at understanding the structure and function of the human genome and its role in health and disease. NHGRI supports the development of resources and technology that will accelerate genome research and its application to human health. A critical part of the NHGRI mission continues to be the study of the ethical, legal and social implications (ELSI) of genome research. NHGRI also supports the training of investigators and the dissemination of genome information to the public and to health professionals. NHGRI Genetics and Molecular Biology Branch (GMBB) investigators use state-of-the-art genetic and genomic technologies to study the genomes of humans and other organisms and disease mechanisms. Their goal is to demonstrate that research findings and opportunities derived from genetic and genomic technologies may be translated into improved diagnosis, treatments and prevention of human diseases. Using the excellent resources of NHGRI intramural laboratories, the NIH Clinical Center and intramural collaborations across NIH, the branch is engaged in basic, translational and clinical research, bringing the latest genomic and genetic technologies to the study of human disease. PROJECT DESCRIPTION : For the past 20 years the FUSION project has been investigating the genetic basis of type 2 diabetes (T2D) by identifying the genomic loci associated with disease using sophisticated statistical analysis of genome wide single nucleotide polymorphisms (SNPs). To translate these genetic associations to functional use we employ methods to differentiate expression of genes from each chromosome and to detect rare events. The FUSION project (Finland - United States Investigation Of NIDDM) began with linkage studies of affected sib pairs, and then moved on to perform a genome-wide association study (GWAS) on a total of 1,200 cases and 1,200 controls using the Illumina 317K genome-wide single-nucleotide polymorphism (SNP) panel. Several interesting associations were tested in stage 2 analysis of a larger number of case and control samples. In combination with data shared from other large association studies of T2D,18 susceptibility loci were identified. Subsequently the FUSION project has become an integral part in several worldwide consortia studying T2D and quantitative traits. To date these consortia have identified over 30 susceptibility loci for T2D and hundreds of loci affecting glucose, BMI, and lipid quantitative traits. JUSTIFICATION: To implement this analysis NHGRI require the ability to detect individual allele representation with substantial accuracy and at a significantly resolution. The optimal method for achieving this level of accuracy and resolution is digital droplet PCR methodology. The ability to compartmentalize PCR reactions in oil immersion is required to perform PCR amplification reactions in up to 20,000 uniform reactions and detect the fluorescent events in each reaction to achieve detection sensitivities as low as 1/100,000 events in an efficient, timely and cost effective manner. The BioRad QX200 Digital Droplet PCR System achieves the objective necessary to complete the analysis required to satisfy the accuracy, resolution and sensitivity that our project requires. The QX200 Droplet Digital PCR system provides an absolute measure of target DNA molecules with unrivaled precision and sensitivity. The QX200 droplet generator partitions samples into thousands of nanoliter-sized droplets, each of which is an independent PCR reactor. After PCR on a thermal cycler, droplets are streamed in single file on the QX200 droplet reader to count the positive and negative reactions. The QX200 Droplet Digital PCR system delivers an absolute count of the number of target DNA sequences for applications that include copy number variation, mutation detection, and gene expression analysis. The QX200 droplet generator partitions a 20 μl PCR reaction into 20,000 nanoliter-sized droplets. Each droplet is approximately 1 nl and has a diameter of approximately 120 μm. PERIOD OF PERFORMANCE : Upon Award REGULATORY AUTHORITY : This acquisition is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1(b) Soliciting from a single source, only one responsible source and no other supplies or services will satisfy agency requirements. ADDITIONAL INFORMATION : Industry Classification (NAICS) Code is 334516, Analytical Laboratory Instrument Manufacturing and the Small Business Size Standard is 500 Employees. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-76 (August 25, 2014). This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by September 4, 2014, 7:30 a.m. Eastern Standard Time and must reference synopsis number HHS-NIH-NHLBI-CSB-(HG)-2014-241-DLM, may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-(HG)-2014-241-DLM/listing.html)
- Record
- SN03484116-W 20140829/140828023245-229d671b6af0c58885ca130a6f3dfa59 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |